Novo Nordisk to Repurchase DKK 15 Billion in Shares

DKK 15 Billion Program: Novo Nordisk will repurchase its own shares over a <strong class="body_output text-content_primary font-semibold" node="[object Object]">12-month period as part of a capital return strategy.
EPS Accretion: By reducing the number of shares outstanding, the buyback is structured to mechanically <strong class="body_output text-content_primary font-semibold" node="[object Object]">increase the company&#x27;s earnings per share (EPS) .
Price Support: The consistent demand from the repurchase program is anticipated to <strong class="body_output text-content_primary font-semibold" node="[object Object]">create a stable floor for the stock price and reduce volatility.

Novo Nordisk Commits DKK 15 Billion to 12-Month Buyback

Novo Nordisk announced on March 9, 2026, that it has initiated a share repurchase program of up to DKK 15 billion. The program, which formally began on February 4, 2026, is scheduled to run for a full 12-month period. The buyback is being executed in compliance with the European Union's Market Abuse Regulation (MAR), specifically under the 'Safe Harbour Rules,' which govern such corporate actions to ensure transparency and prevent market manipulation.

This capital allocation strategy is designed to directly enhance shareholder value. By reducing the total number of shares in circulation, the program will mechanically increase Novo Nordisk's earnings per share (EPS), a key metric used by investors to assess profitability. Furthermore, the steady purchasing activity from the company itself is expected to create consistent demand for the stock. This can provide a level of price support, absorbing selling pressure and potentially lowering the stock's day-to-day volatility, signaling management's confidence in the company's financial outlook.

Novo Nordisk Commits DKK 15 Billion to 12-Month Buyback

Buyback Aims to Boost EPS and Stabilize Share Price